Long-term survival in immunotherapy treated patients with unresectable advanced melanoma

Over the past 10 years several effective new therapies have been developed for patients with advanced melanoma. Since 2010, the primary endpoint of every major phase III trial in this setting has been met, revolutionizing the treatment options and survival for patients with unresectable advanced melanoma. With increasing numbers of patients experiencing durable remissions with these agents, even without continuing therapy, the issue of melanoma survival care becomes of relevance to more patients than ever before.

Jaar van publicatie:2018

Toegankelijkheid:Closed